Capital Fund Management (CFM)’s Neurocrine Biosciences NBIX Stock Holding History

Capital Fund Management (CFM)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,600	Closed	-$658K	–	1382
2020 Q1	$658K	Sell	7,600 -7,700	-50%	-$754K	0.01%	942
2019 Q4	$1.65M	Buy	+15,300	New	+$1.6M	0.01%	914
2019 Q1	–	Sell	-8,300	Closed	-$593K	–	1956
2018 Q4	$593K	Sell	8,300 -31,200	-79%	-$2.99M	0.01%	1297
2018 Q3	$4.86M	Buy	+39,500	New	+$4.48M	0.03%	776
2018 Q2	–	Sell	-59,200	Closed	-$4.91M	–	2187
2018 Q1	$4.91M	Buy	+59,200	New	+$5M	0.03%	688

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Fund Management (CFM)'s NBIX Position: Q1 2026 in Review

Capital Fund Management (CFM) increased its Neurocrine Biosciences (NBIX) stake by 87% in Q1 2026, buying an estimated $9.22M and bringing the position to 149,631 shares worth $19.7M. The position accounts for 0.09% of the portfolio, ranked #314.

Capital Fund Management (CFM) first reported a position in NBIX in Q2 2015 and has held it in 25 quarters since. The position peaked at $25.6M in Q2 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Capital Fund Management (CFM) held 149,631 shares of Neurocrine Biosciences worth $19.7M as of Q1 2026.
Capital Fund Management (CFM) bought 69,506 Neurocrine Biosciences shares in Q1 2026, an estimated $9.22M.
Neurocrine Biosciences made up 0.09% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #314 holding.
Capital Fund Management (CFM) first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 25 quarters since.
Capital Fund Management (CFM)'s Neurocrine Biosciences position peaked at $25.6M in Q2 2025.
695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.